{"nctId":"NCT00141817","briefTitle":"Study Evaluating Pantoprazole in Children With GERD","startDateStruct":{"date":"2005-08"},"conditions":["Gastroesophageal Reflux"],"count":41,"armGroups":[],"interventions":[{"name":"pantoprazole for approximately 9 weeks.","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Endoscopically proven GERD diagnosed within 6 months before study entry.\n* Weight must be equal to or over 8.3 kg; for subjects 6 years or greater, weight must be equal to or under 25 kg\n\nExclusion Criteria:\n\n* History of GI disorders, ie, unrepaired tracheal esophageal fistula, GI malabsorption, Eosinophilic esophagitis\n* Subjects 6-11 years old unable to swallow tablets","healthyVolunteers":false,"sex":"ALL","minimumAge":"1 Year","maximumAge":"11 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Maximum Observed Plasma Concentration (Cmax)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"136","spread":"127"},{"groupId":"OG001","value":"798","spread":"729"},{"groupId":"OG002","value":"1643","spread":"1229"},{"groupId":"OG003","value":"2067","spread":"1320"}]}]}]},{"type":"PRIMARY","title":"Time to Reach Maximum Observed Plasma Concentration (Tmax)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.45","spread":"0.69"},{"groupId":"OG001","value":"2.71","spread":"1.25"},{"groupId":"OG002","value":"2.08","spread":"0.75"},{"groupId":"OG003","value":"2.03","spread":"0.74"}]}]}]},{"type":"PRIMARY","title":"Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)]","description":"AUC (0-t)= Area under the plasma concentration versus time curve from time zero (predose) to time of last quantifiable concentration (0-t).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"208.96","spread":"197.54"},{"groupId":"OG001","value":"2273.96","spread":"1885.68"},{"groupId":"OG002","value":"2448.61","spread":"2007.21"},{"groupId":"OG003","value":"3190.96","spread":"2137.91"}]}]}]},{"type":"PRIMARY","title":"Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]","description":"AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (predose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"293.29","spread":"146.41"},{"groupId":"OG001","value":"2448.08","spread":"2170.48"},{"groupId":"OG002","value":"2497.13","spread":"2099.64"},{"groupId":"OG003","value":"3782.49","spread":"1837.42"}]}]}]},{"type":"PRIMARY","title":"Plasma Decay Half-Life (t1/2)","description":"Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.34","spread":"7.39"},{"groupId":"OG001","value":"1.68","spread":"0.64"},{"groupId":"OG002","value":"0.77","spread":"0.22"},{"groupId":"OG003","value":"0.70","spread":"0.16"}]}]}]},{"type":"PRIMARY","title":"Apparent Oral Clearance (CL/F)","description":"Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.08","spread":"1.27"},{"groupId":"OG001","value":"1.28","spread":"1.16"},{"groupId":"OG002","value":"0.41","spread":"0.30"},{"groupId":"OG003","value":"0.40","spread":"0.22"}]}]}]},{"type":"PRIMARY","title":"Terminal-Phase Volume of Distribution (Vz/F)","description":"Vz/F was calculated as the ratio of clearance (CL) to terminal disposition rate constant (λz).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.22","spread":"14.68"},{"groupId":"OG001","value":"2.89","spread":"2.92"},{"groupId":"OG002","value":"0.43","spread":"0.30"},{"groupId":"OG003","value":"0.40","spread":"0.27"}]}]}]},{"type":"PRIMARY","title":"Plasma Concentrations After Multiple Doses","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"212.30","spread":"222.08"},{"groupId":"OG001","value":"486.49","spread":"605.22"},{"groupId":"OG002","value":"592.32","spread":"914.57"},{"groupId":"OG003","value":"2337.89","spread":"1817.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"503.25","spread":"1087.91"},{"groupId":"OG001","value":"207.23","spread":"211.92"},{"groupId":"OG002","value":"123.83","spread":"163.78"},{"groupId":"OG003","value":"200.78","spread":"209.81"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":7},"commonTop":["Abdominal pain","Diarrhea","Accidental injury","Vomiting","Upper respiratory infection"]}}}